Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan Shinro Takai, MD, PhD, Masao Akagi, MD, PhD, Bruce Crawford, MA, MPH, Sadafumi Ichinohe, MD, PhD, Tokifumi Majima, MD, PhD, Hiroshi Mikami, MD, PhD, Yasuo Niki, MD, PhD, Sakae Tanaka, MD, PhD, Hiroshi Tsumura, MD, PhD Value in Health Regional Issues Volume 2, Issue 1, Pages 81-86 (May 2013) DOI: 10.1016/j.vhri.2013.01.001 Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 1 Time course of VTE incidence following MOS. MOS, major orthopaedic surgery; VTE, venous thromboembolism. Value in Health Regional Issues 2013 2, 81-86DOI: (10.1016/j.vhri.2013.01.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 2 Mean 90-day costs by category for patients with VTE and matched control patients. VTE, venous thromboembolism. Value in Health Regional Issues 2013 2, 81-86DOI: (10.1016/j.vhri.2013.01.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions
Fig. 3 Cumulative mean costs (JPY) from 30 days prior to MOS through 6 months after surgery in patients with VTE and matched control patients. MOS, major orthopaedic surgery; VTE, venous thromboembolism. Value in Health Regional Issues 2013 2, 81-86DOI: (10.1016/j.vhri.2013.01.001) Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions